Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11347682 | PMC |
| http://dx.doi.org/10.1136/bmjonc-2024-000418 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recall of ibrutinib and issues with therapeutic approval.
BMJ Oncol
August 2024
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
The Effect of Rapamycin and Ibrutinib on Antibody Responses to Adeno-Associated Virus Vector-Mediated Gene Transfer.
Hum Gene Ther
June 2022
Wistar Institute, Philadelphia, Pennsylvania, USA.
Adeno-associated virus (AAV) vector-mediated gene transfer is lessening the impact of monogenetic disorders. Human AAV gene therapy recipients commonly mount immune responses to AAV or the encoded therapeutic protein, which requires transient immunosuppression. Most efforts to date have focused on blunting AAV capsid-specific T cell responses, which have been implicated in elimination of AAV-transduced cells.
View Article and Find Full Text PDFDynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy.
Oncoimmunology
January 2018
Department of Oncology and Hematology, BMT with section Pneumology, Hubertus Wald Tumorzentrum / UCCH, University Medical Center Hamburg-Eppendorf, Martinistraße, Hamburg, Germany.
Using next-generation immunoglobulin () sequencing and flow cytometry, we characterized the composition, diversity and dynamics of non-malignant B cells in patients undergoing treatment with the Bruton tyrosine kinase (BTK) inhibitor ibrutinib or chemo-immunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR). During ibrutinib therapy, non-malignant B cell numbers declined, but patients maintained stable diversity and constant fractions of -mutated B cells. This indicates partial preservation of antigen-experienced B cells during ibrutinib therapy, but impaired replenishment of the normal B cell pool with naïve B cells.
View Article and Find Full Text PDFIbrutinib suppresses alloantibody responses in a mouse model of allosensitization.
Transpl Immunol
December 2017
Comprehensive Transplant Center at Cedars-Sinai Medical Center, 9700 Beverly Blvd, Los Angeles, CA 90048, USA.
Background: Ibrutinib is a Bruton's tyrosine Kinase (BTK) antagonist that inhibits B cell receptor (BCR) signaling. Complete BTK deficiency is associated with absence of B-cells. Ibrutinb is currently approved by FDA for treatment of B-cell malignancies, including Waldenström macroglobulinaemia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!